{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-004208","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.107646+00:00","generated_at":"2026-06-26T18:39:04.330251+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"HOOKIPA reports FY2021 net loss of $75.7M; pro-forma cash $156.9M extends runway to H1 2024","bullets":["Net loss widened to $75.7M in FY2021 from $44.1M in FY2020; R&D expenses rose to $82.9M.","Pro-forma cash of $156.9M (Dec 31, 2021) reflects $35M Gilead equity, $15M fee, and $70M follow-on proceeds.","Gilead HIV program advanced, triggering $54M commitment; $4M milestone, $15M fee, $35M equity at premium.","HB-200 Phase 2 combo with pembrolizumab in HNSCC dosed Jan 2022; initial data expected H2 2022.","Klaus Orlinger promoted to CSO; executive team accepted 50% of 2021 bonus in options at $3/share."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-004208","json":"https://secwatch.observer/filing/0001558370-22-004208.json","markdown":"https://secwatch.observer/filing/0001558370-22-004208.md","text":"https://secwatch.observer/filing/0001558370-22-004208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837022004208/0001558370-22-004208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837022004208/hook-20220324x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T18:39:04.330251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}